Literature DB >> 21883703

Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter.

J Schwille-Kiuntke1, P Enck, C Zendler, M Krieg, A V Polster, S Klosterhalfen, I B Autenrieth, S Zipfel, J-S Frick.   

Abstract

BACKGROUND: Gastrointestinal infections have been proposed to predict subsequent irritable bowel syndrome (IBS) but large-scale infectious events are rare and long-term data are missing.
METHODS: We identified 576 individuals with a Salmonella or Campylobacter infection between 2000 and 2009 that were followed by a short postal questionnaire asking for the presence of current symptoms in 2010. In case of agreement (n = 90), an extended postinfectious (PI)-IBS questionnaire was mailed including the Hospital Anxiety Depression Scale and the Patient Health Questionnaire. KEY
RESULTS: A total of 189 patients reported back (36%); 98 had a Salmonella and 91 had a Campylobacter infection, of which 56 reported persistent symptoms (9.7% of the initial sample). Fifty-one patients returned the PI-IBS questionnaire. Of 48 patients with complete data, 15 reported no or mild symptoms of abdominal pain or discomfort while 17 had moderate and 16 severe symptoms. Twenty-two met Rome IBS criteria, 14 (29%) reported GI symptoms before the infection. Patients with moderate and/or severe PI-IBS symptoms were significantly more often females, were more often infected by Salmonella than by Campylobacter, had more severe symptoms during the initial infection, and had more often GI symptoms prior to the infection. They reported higher anxiety, depression, and somatisation scores, but were not different with respect to acute stool habits. CONCLUSIONS & INFERENCES: Nearly 10% of patients with an intestinal bacterial infection report postinfectious symptoms up to 10 years after the infectious event. They represent a clinically important population with high psychiatric comorbidity and somatic symptom burden.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21883703     DOI: 10.1111/j.1365-2982.2011.01779.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  33 in total

Review 1.  Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis.

Authors:  Fabiane Klem; Akhilesh Wadhwa; Larry J Prokop; Wendy J Sundt; Gianrico Farrugia; Michael Camilleri; Siddharth Singh; Madhusudan Grover
Journal:  Gastroenterology       Date:  2017-01-06       Impact factor: 22.682

Review 2.  Global Epidemiology of Campylobacter Infection.

Authors:  Nadeem O Kaakoush; Natalia Castaño-Rodríguez; Hazel M Mitchell; Si Ming Man
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

3.  [Etiopathogenetic aspects of somatoform disorders].

Authors:  M Noll-Hussong; H Gündel
Journal:  Nervenarzt       Date:  2012-09       Impact factor: 1.214

4.  Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease.

Authors:  Olga C Aroniadis; Lawrence J Brandt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-04

Review 5.  IBS and IBD - separate entities or on a spectrum?

Authors:  Robin Spiller; Giles Major
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-26       Impact factor: 46.802

Review 6.  Irritable bowel syndrome, the microbiota and the gut-brain axis.

Authors:  Hans Raskov; Jakob Burcharth; Hans-Christian Pommergaard; Jacob Rosenberg
Journal:  Gut Microbes       Date:  2016-07-29

7.  Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating.

Authors:  Tamar Ringel-Kulka; Johnson McRorie; Yehuda Ringel
Journal:  Am J Gastroenterol       Date:  2016-11-15       Impact factor: 10.864

Review 8.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

Review 9.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

10.  High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.

Authors:  A Wadhwa; M F Al Nahhas; R A Dierkhising; R Patel; P Kashyap; D S Pardi; S Khanna; M Grover
Journal:  Aliment Pharmacol Ther       Date:  2016-07-22       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.